Table of Contents
- Clinical trial overview
- Who is being studied
- What the study measures
- Study design and phase
- Why this research matters
Clinical trial overview
The available trial for “[18F]CPFPX” is an interventional study, which means researchers are using a planned test procedure and measuring the results.[1] It is focused on neurology and specifically on people with drug-resistant epilepsy, while also including healthy subjects for comparison.[1]
The study title says it is about the impact of epilepsy on the brainstem adenosine pathway and how this relates to arousal and respiratory reactivity.[1] The brief summary states that the trial compares brain imaging findings with [18F]-CPFPX PET in brainstem structures involved in respiratory regulation under a hypercapnic condition.[1]
Who is being studied
This trial includes patients with drug-resistant epilepsy and healthy subjects.[1] The healthy group is used as a comparison group, so researchers can see whether the brain imaging results are different in epilepsy.[1]
The trial data do not give more detailed eligibility rules, such as age limits or other health requirements.[1] The enrollment is 50 participants in total.[1]
What the study measures
The main outcome is the comparison of [18F]-CPFPX BPND in brainstem structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy and healthy subjects.[1] BPND is a PET scan measurement that helps describe how much tracer is bound in a brain area.[1]
In simple terms, the study is trying to see whether the brainstem pattern seen on PET imaging changes when carbon dioxide levels are increased, and whether this differs between groups.[1] The trial also links these findings to arousal and breathing-related responses.[1]
Study design and phase
The trial is listed as Phase 2.[1] Phase 2 studies are early clinical studies that test how a study procedure performs in people and what it can measure.[1]
The status is Authorised, which means the study has been approved to move forward.[1] The intervention listed is [18F]CPFPX given by injection at 275 MBq.[1]
Why this research matters
This research may help explain how epilepsy affects brain areas that control breathing and alertness.[1] It may also help researchers compare patients with healthy subjects using a brain imaging method that can show differences in specific brainstem structures.[1]
Because the study focuses on a breathing challenge, it is aimed at understanding respiratory regulation, which means how the body keeps breathing stable.[1] The trial does not provide results yet, so its purpose is mainly to measure and compare brain imaging findings.[1]
